Nchi: Armenia
Lugha: Kiingereza
Chanzo: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
meloxicam
Boehringer Ingelheim Ellas A.E.
M01AC06
meloxicam
15mg
tablets
(20/2x10/) in blister
Prescription
Registered
2017-03-17
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Movalis 15 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 15 mg of Meloxicam. Excipient(s) with known effect Each tablet contains 19.0 mg lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Light yellow round scored tablet with the logotype of the company on one side and a score with 77C/77C on the other side. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - Short-term symptomatic treatment of exacerbations of osteoarthrosis - Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis - Movalis tablets are indicated in adults and children aged 16 years and older 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The total daily amount should be taken as a single dose. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis. - Exacerbations of osteoarthrosis: 7.5 mg/day (half a 15 mg tablet). If necessary, in the absence of improvement, the dose may be increased to 15 mg/day (one 15 mg tablet). - Rheumatoid arthritis, ankylosing spondylitis: 15 mg/day (one 15 mg tablet) (see also section ‘Special populations below). According to the therapeutic response, the dose may be reduced to 7.5 mg/day (half a 15 mg tablet). DO NOT EXCEED THE DOSE OF 15 MG/DAY. Special populations _Elderly patients (see section 5.2) _ The recommended dose for long term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg per day (see also sections 4.2 ‘Patients with increased risks for adverse reaction’ and 4.4). _Patients with increased risks for adverse reaction (see section 4.4) _ In patients with increased risks for adverse reactions, e.g. a history of gastro Soma hati kamili